A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment

Ceftolozane-tazobactam is considered to be a last-resort treatment for infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Although resistance to this antimicrobial has been described in vitro, the development of resistance in vivo has rarely been reported. Here, we describe the e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Boulant, Thibaud, Jousset, Agnès B., Bonnin, Rémy A., Barrail-Tran, Aurélie, Borgel, Adrien, Oueslati, Saoussen, Naas, Thierry, Dortet, Laurent
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2019
Matèries:
Mechanisms of Resistance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6879234/
https://ncbi.nlm.nih.gov/pubmed/31636072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01637-19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars